Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Accumulated Expenses (2023 - 2025)

Upstream Bio has reported Accumulated Expenses over the past 3 years, most recently at $4.2 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $4.2 million for Q4 2025, down 30.04% from a year ago — trailing twelve months through Dec 2025 was $4.2 million (down 30.04% YoY), and the annual figure for FY2025 was $4.2 million, down 30.04%.
  • Accumulated Expenses for Q4 2025 was $4.2 million at Upstream Bio, up from $3.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for UPB hit a ceiling of $7.7 million in Q2 2025 and a floor of $669000.0 in Q3 2024.
  • Median Accumulated Expenses over the past 3 years was $4.1 million (2025), compared with a mean of $4.0 million.
  • Peak annual rise in Accumulated Expenses hit 353.96% in 2025, while the deepest fall reached 30.04% in 2025.
  • Upstream Bio's Accumulated Expenses stood at $2.2 million in 2023, then surged by 176.38% to $6.0 million in 2024, then crashed by 30.04% to $4.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $4.2 million (Q4 2025), $3.0 million (Q3 2025), and $7.7 million (Q2 2025) per Business Quant data.